Literature DB >> 890909

Detection of heterozygotes for phenylketonuria. Total body phenylalanine clearance and concentrations of phenylalanine and tyrosine in the plasms of fasting subjects compared.

R Jagenburg, C G Regårdh, S Rödjer.   

Abstract

Two tests have been compared for detection of heterozygotes for phenylketonuria, one based on determination of plasma phenylalanine and tyrosine concentrations in fasting individuals and the other on kinetic evaluation of the plasma elimination curve after intravenous loading with L-phenylalanine. The plasma elimination curve was biexponential and the kinetics were evaluated according to the two-compartment model. The constant, beta, expressing the rate of elimination from plasma at pseudo-equilibrium, the rate constant for the elimination from the central compartment, and the total body clearance were determined. Of these three, total body clearance, which on the average was reduced by 32% in the phenylketonuric heterozygotes, showed the best discriminatory ability, but was not better than the information on concentrations of phenylalanine and tyrosine in detecting heterozygotes for phenylketonuria.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 890909

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  Modelling amino acid metabolism.

Authors:  M Hjelm; J Seakins
Journal:  Amino Acids       Date:  1992-02       Impact factor: 3.520

2.  Significant phenylalanine hydroxylation in vivo in patients with classical phenylketonuria.

Authors:  G N Thompson; D Halliday
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

3.  Absent phenylalanine hydroxylase activity without phenylketonuria.

Authors:  M Yudkoff; S Segal
Journal:  Eur J Pediatr       Date:  1980-06       Impact factor: 3.183

4.  Gender dimorphism in aspartame-induced impairment of spatial cognition and insulin sensitivity.

Authors:  Kate S Collison; Nadine J Makhoul; Marya Z Zaidi; Soad M Saleh; Bernard Andres; Angela Inglis; Rana Al-Rabiah; Futwan A Al-Mohanna
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.